Stockscreener 앱 받기
2.01
4.15%
0.08
Gain Therapeutics Inc 주식(GANX)의 최신 뉴스
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - sharewise
Northern Trust Corp Invests $208,000 in Inhibikase Therapeutics, Inc. (NYSE:IKT) - Defense World
Gain Therapeutics, Inc. (NASDAQ:GANX) Shares Purchased by Northern Trust Corp - Defense World
i-80 Gold Corp. (NYSE:IAUX) Receives $3.50 Average PT from Brokerages - Defense World
Northern Trust Corp Increases Stock Holdings in PetMed Express, Inc. (NASDAQ:PETS) - Defense World
Northern Trust Corp Purchases 10,466 Shares of United-Guardian, Inc. (NASDAQ:UG) - Defense World
Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews
Lantern Pharma Inc. (LTRN)’s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models - Yahoo Finance
Gain Therapeutics, Inc. Announces Oral Presentation at GBA1 Meeting 2025 in Montreal - Nasdaq
Gain Therapeutics' Chief Medical Officer Set to Reveal Latest GBA1 Therapeutic Developments in Montreal - Stock Titan
Gain Therapeutics Files $100 Million Mixed Shelf - marketscreener.com
Gain Therapeutics (GANX) Pursues $100 Million Securities Offerin - GuruFocus
Gain Therapeutics (GANX) Pursues $100 Million Securities Offering | GANX Stock News - GuruFocus
US Stocks Gain; Abercrombie & Fitch Posts Upbeat Earnings - Benzinga
CytomX Therapeutics Inc’s (CTMX) 4.41% Gain Is A Reason To Reconsider. - Stocksregister
HC Wainwright Brokers Increase Earnings Estimates for GANX - Defense World
Gotham Asset Management LLC Sells 176,437 Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of “Buy” by Analysts - Defense World
GM1 Gangliosidosis Market: Epidemiology, Therapies, - openPR.com
Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC Wainwright - Defense World
Gain Therapeutics (GANX) Maintains 'Buy' Rating with $8 Price Ta - GuruFocus
Roth Capital Predicts Reduced Earnings for Gain Therapeutics - Defense World
Gain Therapeutics Reports Q1 2025 Financial Results - TipRanks
Gain Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Gain (GANX) Advances Parkinson's Treatment in Phase 1b Trials | - GuruFocus
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update - The Manila Times
Gain Therapeutics, Inc. Reports Q1 2025 Financial Results and Corporate Update, Highlights Progress in Parkinson’s Disease Drug Development - Nasdaq
Gain Therapeutics' Parkinson's Drug Shows Promise: Key Biomarker Data Coming Mid-2025 - Stock Titan
Zevra Therapeutics Q1 Net Loss Narrows, Revenue Rises; Shares Gain After Hours - marketscreener.com
Crude Oil Gains 3%; US Inflation Eases In April - Benzinga
Gain Therapeutics (GANX) Showcases Promising Parkinson's Treatme - GuruFocus
Gain Therapeutics, Inc. Presents New Evidence for GT-02287 as Potential Disease-Modifying Therapy for Parkinson’s Disease at IAPRD 30th World Congress - Nasdaq
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - The Manila Times
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders - TradingView
Gain Therapeutics (GANX) Expected to Announce Earnings on Tuesday - Defense World
Halozyme Therapeutics, Inc. (HALO): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Insider Monkey
Summit Therapeutics Inc. (SMMT): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance
Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance
TG Therapeutics, Inc. (TGTX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance
Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain - Yahoo Finance
Gaining Ground: Verve Therapeutics Inc (VERV) Closes Lower at 5.95, Down -11.33 - DWinneX
Closing Figures Unveiled: Indaptus Therapeutics Inc (INDP) Gain 7.96, Closes at 0.71 - DWinneX
Market Insights: Trevi Therapeutics Inc (TRVI)’s Notable Gain of 1.22, Closing at 6.66 - DWinneX
Gain Therapeutics Inc (GANX) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Market Watch: Soleno Therapeutics Inc (SLNO)’s Noteworthy Gain, Closing at 75.02 - DWinneX
Gain Therapeutics Inc [GANX] Records 50-Day SMA of $1.9700 - knoxdaily.com
Gaining Ground: SpringWorks Therapeutics Inc (SWTX) Closes Higher at 46.30, Up 0.13 - DWinneX
Gain Therapeutics Inc (GANX) Stock: Navigating Drops and Gains - investchronicle.com
Market Watch: ITeos Therapeutics Inc (ITOS)’s Noteworthy Gain, Closing at 7.25 - DWinneX
Gain Therapeutics to Participate at The Citizens Life Sciences Conference - Eagle-Tribune
Gain Therapeutics Inc (GANX) deserves deeper analysis - uspostnews.com
Gain Therapeutics CEO to Showcase Next-Gen Allosteric Therapies at Major Healthcare Conference - Stock Titan
Gain Therapeutics Announces Oral Poster Presentation - marketscreener.com
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related Disorders - The Manila Times
Gain Therapeutics, Inc. Announces Oral Poster Presentation of GT-02287 for Parkinson's Disease at IAPRD 30th World Congress - Nasdaq
Breakthrough: Novel Drug GT-02287 Demonstrates Neuroprotective Effects in Parkinson's Disease - Stock Titan
Protara Therapeutics, Inc.'s (NASDAQ:TARA) institutional investors lost 14% last week but have benefitted from longer-term gains - simplywall.st
Gaining Ground: Structure Therapeutics Inc ADR (GPCR) Closes Lower at 23.62, Down -0.51 - DWinneX
Abeona stock gains on FDA nod for gene therapy (ABEO:NASDAQ) - Seeking Alpha
Gaining Ground: Abeona Therapeutics Inc (ABEO) Closes Lower at 4.84, Down -0.21 - DWinneX
CERo Therapeutics Holdings Inc [CERO] is -81.50% lower this YTD. Is it still time to buy? - dbtnews.com
EOM Pharmaceuticals (OTCMKTS:IMUC) Stock Price Down 0.8% – Time to Sell? - American Banking and Market News
Market Insights: Denali Therapeutics Inc (DNLI)’s Notable Gain of 4.17, Closing at 15.49 - DWinneX
Gain Therapeutics (NASDAQ:GANX) Stock Price Up 1.6% – Here’s Why - American Banking and Market News
Gain Therapeutics (NASDAQ:GANX) Trading Up 1.6% – Here’s Why - Defense World
GANXGain Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Gaining Ground: Tango Therapeutics Inc (TNGX) Closes Lower at 2.35, Down -0.42 - DWinneX
Gaining Ground: SpringWorks Therapeutics Inc (SWTX) Closes Higher at 41.21, Up 1.75 - DWinneX
0.87%
0.19%
자본화:
|
볼륨(24시간):